CCCC C4 Therapeutics

C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022

C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022

WATERTOWN, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that C4T management will participate in a fireside chat at the virtual Bank of America Securities Precision Oncology Conference 2022.

Presentation Details:

Event: Bank of America Securities Precision Oncology Conference 2022

Date/Time: Monday, October 3rd, 2022 at 9:50 a.m. ET

A live webcast of the presentation will be available on the Investors section of the company’s website at . An archived replay of the webcast will be available for approximately 30 days following the presentation.

About C4 Therapeutics

C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines that harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. C4T is advancing multiple targeted oncology programs to the clinic and expanding its research platform to deliver the next wave of medicines for difficult-to-treat diseases. For more information, please visit .

Investor Contact: 

Courtney Solberg 

Senior Manager, Investor Relations 

Media Contact: 

Loraine Spreen 

Director, Corporate Communications & Patient Advocacy





EN
26/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on C4 Therapeutics

 PRESS RELEASE

C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare C...

C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference WATERTOWN, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference taking place from December 2 - 4, 2025 in Coral Gables, Florida. Fireside Chat Details:Event: 8th Annual Evercore Healthcare ConferenceDate/Time: Wednesday, December 3rd, 2025 at 3:25 pm ET A ...

 PRESS RELEASE

C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recen...

C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights Completed Equity Offering Resulted in $125 Million in Gross Proceeds, Extending Runway to End of 2028, Beyond Key Value Inflection Points; Potential to Earn up to an Additional $225 Million in Proceeds Cemsidomide Phase 1 Multiple Myeloma Data Support Potential Best-in-Class Profile With a 53% Overall Response Rate at the Highest Dose Level (100 µg) and Differentiated Safety and Tolerability Profile  Entered Into Clinical Trial Collaboration and Supply Agreement With Pfizer to Evaluate Cemsidomide ...

 PRESS RELEASE

C4 Therapeutics Announces Pricing of $125 Million Underwritten Offerin...

C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering $125 Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial in Combination with Dexamethasone and Phase 1b Trial in Combination with Elranatamab Potential to Earn up to an Additional $225 Million in Proceeds WATERTOWN, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the pricing o...

 PRESS RELEASE

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agre...

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer Inc. Under the terms of the agreement, Pfizer will supply elranatamab (ELREXFIO®), a B-cell m...

 PRESS RELEASE

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Sup...

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma Patient Population Responses Across Dose Levels With Median Duration of Response of 9.3 Months as of the Data Cut-off Date; Median Duration of Response Not Yet Reached at Two Highest Doses No Discontinuations ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch